Peptide injected directly into the tumor to break open cancer cells and awaken the immune system against them. In early trials in solid tumors.
Regulatory status
In clinical trials
Family
Oncolytic peptide (derived from antimicrobial peptides)
Scientific evidence
Low
Number of findings
2
Where it acts
Immunity and defense
Also known as
LTX-315, ruxotemitide, Oncopore
Regulatory status
FDA (US): Not approved (phase 1–2 trials)
EMA (EU): Not approved
Dose
There is no established dose in humans.
Safety
In phase 1, transient drops in blood pressure (46%), facial flushing (28%), and injection-site reactions (38%) were frequent. About 10% had grade 3 allergic reactions or anaphylaxis. Only in oncology clinical trials.
Effect by goal · level of evidence
Local antitumor activity and immune response in solid tumors
improvesLowclinical trial (A)in people
29% local tumor reduction
Phase 1 with 39 patients with advanced tumors: 29% had a ≥30% reduction in injected tumors, and 86% of biopsies showed more CD8+ T cells. There were no partial responses by immune-related criteria.
Combination with lymphocyte therapy in metastatic sarcoma
no clear effectLowclinical trial (A)in people
Pilot study with 6 heavily pretreated patients: the best response was stable disease lasting 208 days, with generation of tumor-specific T cells. Treatment considered safe.
A positively charged peptide that punctures the membrane of tumor cells and of their mitochondria, causing a cell death that releases alarm signals. These signals attract and activate T cells, which can also attack non-injected tumors.
What the evidence says
In people
Local antitumor activity and immune response in solid tumors. Phase 1 with 39 patients with advanced tumors: 29% had a ≥30% reduction in injected tumors and 86% of biopsies showed more CD8+ T cells. There were no partial responses by immune-related criteria. PubMed 33542073
Combination with cell therapy in metastatic sarcoma. Pilot study with 6 heavily pretreated patients: the best response was stable disease lasting 208 days, with generation of tumor-specific T cells. Treatment considered safe. PubMed 38125722